AACR OVARIAN CANCER CONFERENCE PRESENTATION

HIGHLIGHTS Data from preclinical studies in ovarian cancer presented at premier international conference in Boston, USA. Results indicate that Amplia's proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care in models...